Key result
Surgery for primary pulmonary angiosarcoma is linked to ~13 months longer median survival versus non-surgical care.
Why the study?
To explore the clinicopathological features, radiographic manifestations, treatment options, and prognosis of primary pulmonary angiosarcoma.
Does surgery improve overall survival in patients with primary pulmonary angiosarcoma compared to non-surgical management?
Observational (n=11)
No
Does surgery improve overall survival in patients with primary pulmonary angiosarcoma compared to non-surgical management?
Primary pulmonary angiosarcoma is a rare, highly aggressive malignancy with a poor prognosis, though surgical resection may offer a survival benefit in selected cases.
Answers are grounded in this paper and cite their sources.
May support surgery in selected cases; leaves open survival benefit given small observational data.
OBJECTIVE: The aim of this study is to explore the clinicopathological features, radiographic manifestations, treatment options, and prognosis of primary pulmonary angiosarcoma (PPAS). METHOD: We summarized and analyzed the clinical data of 11 patients with primary pulmonary angiosarcoma treated at the First Affiliated Hospital of Guangzhou Medical University between January 2018 and January 2024. A retrospective analysis was conducted in conjunction with a review of the relevant literature. RESULTS: Among the 11 cases, the primary symptoms were nonspecific respiratory issues, with chest pain, cough, and shortness of breath being the most common. Initial diagnosis was correct in only 2 cases, while the remaining 9 cases were misdiagnosed as other conditions, such as lung nodules, infections, or pulmonary embolism. All patients were ultimately diagnosed via pathology, with CD31 and CD34 showing a high positivity rate of 60%. Of the 11 patients, 9 have died, and 2 remain alive. The average survival period was 13.2 months.Based on the number of lesions, PPAS was categorized into three types: solitary, multiple, and invasive pulmonary artery. The average survival period for the solitary type (2 cases) was 15.5 months, for the multiple type (5 cases) was 6.6 months, and for the pulmonary artery type (4 cases) was 20.5 months. Among the 3 patients who underwent surgery, the median overall survival (OS) was 23.0 months, whereas for the 8 non-surgical patients, the median OS was 9.7 months. CONCLUSION: Primary pulmonary angiosarcoma is a rare, highly aggressive vascular malignancy characterized by nonspecific clinical symptoms and a tendency for metastasis and pulmonary artery embolism. Currently, no effective treatment exists, and the overall prognosis is poor.
No takes yet. Share an insight, caveat, or question.
Luan et al. (2024) conducted an observational in Primary pulmonary angiosarcoma (n=11). Surgical resection, chemotherapy, targeted therapy, and immunotherapy was evaluated on Overall survival. Primary pulmonary angiosarcoma is a highly aggressive malignancy with an average survival of 13.2 months, though surgical patients achieved a median overall survival of 23.0 months versus 9.7 months for non-surgical patients.
Synapse has enriched 10 related papers. Consider them for comparative context: